Breaking Finance News

Otonomy Inc (NASDAQ:OTIC) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has upgraded Otonomy Inc(NASDAQ:OTIC) to Hold in a statement released on 8/18/2016.

Having a price of $17.31, Otonomy Inc (NASDAQ:OTIC) traded 1.11% lower on the day. The last stock price close is up 15.69% relative to the 200-day average, compared to the Standard & Poor’s 500 Index which has decreased -0.01% over the same time period. Otonomy Inc has recorded a 50-day average of $16.60 and two hundred day average of $15.39. 325,388 shares of the stock traded, up from ann average trading volume of 203,470

Recent Performance Graphic:

Otonomy Inc (NASDAQ:OTIC)

Otonomy Inc has a 52 week low of $10.50 and a 52 week high of $31.15 . OTIC’s total market value is presently $0.0.

Brief Synopsis About Otonomy Inc (NASDAQ:OTIC)

Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company has developed a technology referred to as sustained-exposure that is designed to deliver drug that is retained in the ear for an extended period of time following a local administration. Its product candidates include OTIPRIO, OTO-104 and OTO-311. The Company’s product candidate, OTIPRIO, is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery. Its product candidate, OTO-104, is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere’s disease and other inner ear conditions. The Company’s product candidate, OTO-311, and is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *